DMC Group LLC Has $972,000 Position in Novo Nordisk A/S (NYSE:NVO)

DMC Group LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,305 shares of the company’s stock after selling 1,061 shares during the quarter. DMC Group LLC’s holdings in Novo Nordisk A/S were worth $972,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Novare Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after buying an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton increased its position in Novo Nordisk A/S by 2.5% during the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the period. Burns J W & Co. Inc. NY raised its stake in Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after purchasing an additional 100 shares in the last quarter. Spinnaker Trust boosted its holdings in Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after purchasing an additional 100 shares during the period. Finally, Marco Investment Management LLC grew its position in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after purchasing an additional 100 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $84.05 on Thursday. The stock has a fifty day moving average of $94.75 and a 200-day moving average of $114.02. The stock has a market capitalization of $377.17 billion, a P/E ratio of 27.20, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.